Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
1.890
-0.100 (-5.03%)
At close: Jun 5, 2026, 4:00 PM EDT
1.880
-0.010 (-0.53%)
After-hours: Jun 5, 2026, 7:00 PM EDT
Annovis Bio Earnings Call Transcripts
Fiscal Year 2025
-
A new orally available Alzheimer's drug targets four toxic proteins, showing both symptomatic and disease-modifying effects in animal and human studies. It demonstrated significant cognitive improvement and broad efficacy across patient subgroups, with an 18-month pivotal trial ongoing.
-
The pivotal phase III Alzheimer's trial is progressing, with full enrollment expected by year-end and key data readouts planned for fall and 2027. Early results show strong efficacy and safety, while Parkinson's studies await funding. Regulatory and investor engagement remains active.